Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Xyzal - Philippines FDA Drug Approval Details

Approvals/Philippines FDA/Xyzal

Approved

STANDARD

Xyzal

UCB Farchim S.A.🇵🇭 Food and Drug Administration - Philippines

Approval Date: Jul 14, 2025
Approval ID: bfbbd082f73d08c7
Company: UCB Farchim S.A.
Type: Standard

Approval Details

Approval Id: bfbbd082f73d08c7
Drug Approval Philippines Name: Xyzal
Product Name: Xyzal
Registration Number: DR-XY28008
Brand Name: Xyzal
Generic Name: Levocetirizine Dihydrochloride
Dosage Form: Film-Coated Tablet
Dosage Strength: 5mg
Manufacturer: UCB Farchim S.A.
Importer: GlaxoSmithKline Philippines, Inc.
Distributor: GlaxoSmithKline Philippines, Inc.
Issuance Date: 24 September 2021
Expiry Date: 31 October 2026
Pharmacologic Category: Antihistamine
Classification: Prescription Drug (Rx)

Active Ingredients

Approved

Quick Info

Agency

Philippines FDA

Country

🇵🇭

Approval Date

Jul 14, 2025

Approval ID

bfbbd082f73d08c7

Type

Standard

Back to Philippines FDA Approvals